Oragenics closed at $0.37 on Nov 4, up 0.51%, within 1.6% of its 52-week closing low. Volume of 4.9K shares was 0.23× its 20-day average (below normal).
Split-adjusted performance: -23.3% over one month, -40.0% over six months, -69.5% over one year.
Short interest was 837.0K shares at the Oct 15 settlement (24.4% of float, 36.7 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| OGENOragenics | $0.3720 | +0.51% | −40.0% | — | — | — | $1.7M | |
| KAPAKairos Pharma | $0.4897 | −3.03% | −87.4% | — | — | — | $1.7M | Compare |
| KPTIKaryopharm Therapeutics | $0.0729 | −17.44% | −99.2% | −11.9% | −200.5% | — | $1.7M | Compare |
| GNPXGenprex | $2.14 | −7.36% | −89.1% | — | — | — | $1.8M | Compare |
| PPCBPropanc Biopharma | $1.79 | +4.68% | −92.9% | — | — | — | $1.8M | Compare |
| ELABPMGC Holdings | $1.92 | −1.03% | −91.0% | — | −225.1% | — | $1.6M | Compare |
| GOVXGeoVax Labs, Inc. New | $0.1680 | +2.38% | −89.8% | −100.0% | — | — | $1.5M | Compare |
| SBFMSunshine Biopharma | $2.65 | −3.28% | −98.8% | −1.6% | −16.9% | — | $2.0M | Compare |
| ARTLArtelo Biosciences | $2.27 | −5.42% | −90.9% | — | — | — | $1.2M | Compare |
No recent articles focused on Oragenics.
Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
